Two founders who grew up with dyslexia set out to fix the slow, costly process of learning-disability evaluation. First they made testing remote and affordable. Then they built the AI report writer that gives evaluators their week back.
MARKER LEARNING — the New York-based platform for special education teams, photographed as its own brand cover. Founders Stefan Bauer and Emily Yudofsky built it from personal experience with dyslexia.
Stefan Bauer and Emily Yudofsky both struggled in school before they were diagnosed with dyslexia. Once identified, both thrived, and both went on to study at Yale. The gap between struggling and thriving was a single thing - a proper evaluation - and for most families that evaluation is expensive, slow and hard to reach.
Marker Learning, founded in 2020 and based in New York, started as a direct answer to that gap. Rather than the traditional in-person route, which can cost thousands of dollars and take months, Marker brought the diagnostic process online. Licensed psychologists conduct initial evaluations and re-evaluations remotely for dyslexia, ADHD, dysgraphia, dyscalculia and auditory and language processing disorders, with early assessments priced around $799.
The clinical foundation was deliberate. Marker's approach was developed with input from leading experts, including from Johns Hopkins, and has been recognized by the International Dyslexia Association and the Learning Disabilities Association. States such as New York, Florida and New Jersey were early adopters, and availability has since expanded across the country.
Then Marker did the harder, sharper thing. It looked at where evaluators actually lose time - not in the testing, but in the writing. A single evaluation report can take a school psychologist the better part of a workday. So Marker built software for the people doing the work: an AI-assisted platform that drafts the report and hands the judgment back to the clinician.
Learning-disability evaluations are costly and slow, and the clinicians who run them spend hours per case writing structured reports. Families wait; caseloads back up; the students who most need answers wait longest.
School districts, special education teams, school and clinical psychologists, and families. Marker sells both to institutions running evaluations and to the individual evaluators writing the reports.
Upload referral and assessment documents; Marker compiles a structured draft - history, background and assessment data - and cites every sentence back to its source. The evaluator interprets and decides.
Plenty of tools now bolt AI onto documentation. Marker's distinguishing bet is trust: every line of a Marker draft can be traced to the document it came from, so an evaluator can verify the source of any statement before signing their name to it.
Two more things separate Marker from generic AI writing tools and from traditional testing clinics. First, compliance is built in, not bolted on: the platform is FERPA and NIST CSF compliant, with adaptive formatting and built-in compliance checks - the difference between a district being able to adopt software or not. Second, clinical credibility. Marker's Chief Clinical Officer, Dr. Samuel O. Ortiz, is a professor of psychology and a nationally recognized expert on nondiscriminatory assessment and Cross-Battery Assessment. "By evaluators, for evaluators" is the company's own framing, and the leadership bench backs it up.
Licensed psychologists run initial evaluations and re-evaluations remotely for dyslexia, ADHD, dysgraphia, dyscalculia and auditory/language processing disorders - at a fraction of traditional private-testing cost.
Upload documents and Marker compiles a structured, citation-backed draft report in minutes, with compliance checks and adaptive formatting - keeping analysis and final judgment with the evaluator.
Tools for special education teams to manage assessments and rating scales, track cases, standardize templates and collaborate across the evaluation workflow.
Marker's $15M Series A, announced in February 2023, was led by Andreessen Horowitz. The round drew an unusual co-investor for special-education software: the venture arm of Richard Branson's Virgin Group. Existing backers followed on.
A dual approach: affordable remote evaluations for families and schools, plus a B2B SaaS subscription selling the AI report-writing and case-management platform to districts and evaluators.
Traditional in-person neuropsychology clinics, in-house district evaluation teams, and newer AI report tools such as BrightSteps AI. Marker's edge is combining clinical credibility with citation-level transparency.
Sitting where health, education and AI overlap - a large, underserved need for learning and attention evaluations, and a special-education workforce squeezed for time.
Stefan Bauer and Emily Yudofsky launch the company to make learning-disability evaluations more accessible.
Funding to build a network of licensed professionals and expand remote assessments into new states.
Andreessen Horowitz leads; Virgin Group and existing investors join to expand geography and services.
Marker launches software that drafts citation-backed special-education evaluation reports.
Dr. Samuel O. Ortiz serves as Chief Clinical Officer, overseeing clinical protocols and standards.
It makes learning-disability evaluations more accessible - originally through affordable remote assessments for conditions like dyslexia and ADHD, and now through an AI-assisted platform that helps special education teams draft citation-backed evaluation reports.
Stefan Bauer (CEO) and Emily Yudofsky, who were both diagnosed with dyslexia as children and later attended Yale.
Roughly $19.7M total, including a $4M seed round in 2021 and a $15M Series A in 2023 led by Andreessen Horowitz with participation from Virgin Group.
School districts, special education teams, school and clinical psychologists, and families seeking evaluations for learning and attention differences.
It is the only report writer that cites every sentence back to its source document, and it is FERPA and NIST CSF compliant - keeping clinical judgment with the evaluator while automating the drafting.